Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Formosa Pharmaceuticals, Inc. (6838.TWO)
Taipei, TW
Formosa Pharmaceuticals, Inc., a biopharmaceutical firm situated in Taipei City, Taiwan, is actively engaged in both late-preclinical and early clinical development stages. Its core focus lies in pioneering therapeutic candidates across ophthalmology, oncology, and anti-infective domains. Among its key investigational assets is APP13007, an ophthalmic nanosuspension, currently progressing through Phase III trials for managing post-surgical discomfort and inflammation of the eye. The company's portfolio also encompasses TSY-0110, designed as an antibody-drug conjugate, and TSY-0210, an antibiotic targeting resilient drug-resistant infections. Further compounds under development include APP13002, a topical antibiotic intended for ocular infections like blepharitis, and MPT0E028, a novel pan-histone deacetylase inhibitor being explored for solid malignancies such as hepatomas and colorectal cancer, in addition to lung fibrosis. Additionally, Formosa Pharmaceuticals maintains a collaborative partnership with Eyenovia, Inc., dedicated to advancing innovative ophthalmic treatments. Established in 2010, the company is headquartered in Taiwan's capital.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.61% | -3.49% | -10.75% | -10.59% | -9.78% | -5.68% | -7.09% | -58.36% | -54.00% | -54.00% | -54.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Biotechnology: +1.6%-93.4% Q1'26: +7,546.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+61.5% ★ Q1'26: +63.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,479.7% Q1'26: -142.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,280.1% Q1'26: -23.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-286.9% Q1'26: -50.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.2% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.37× Q1'26: 2.53× (vs Q1'25)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 11.5K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Erick Co | President & Chief Executive Officer | — | — |
| Heidi Pan | Chief Financial Officer | — | female |
| Wayne Wei | Chief Business & Strategy Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6838.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
